Literature DB >> 31559482

Three-dimensional speckle-tracking echocardiography for the global and regional assessments of left ventricle myocardial deformation in breast cancer patients treated with anthracyclines.

Madalena Coutinho Cruz1, Luísa Moura Branco2, Guilherme Portugal2, Ana Galrinho2, Ana Teresa Timóteo2, Pedro Rio2, Rita Ilhão Moreira2, Tiago Mendonça2, Ana Leal2, Fernanda Gameiro2, Sónia Duarte Oliveira3, Ricardo Luz3, Rui Cruz Ferreira2.   

Abstract

BACKGROUND: Assessment of 2D/3D left ventricular ejection fraction (LVEF) and 2D global longitudinal strain (GLS) is the gold standard for diagnosing cancer therapeutics-related cardiac dysfunction (CTRCD). Although 3D speckle-tracking echocardiography (STE) has several advantages, it is not used in this setting.
METHODS: 105 breast cancer patients who underwent serial echocardiographic assessment during anthracycline therapy were included. STE was used to estimate 2D GLS, 3D GLS, 3D global circumferential strain (GCS), 3D global radial strain (GRS), and 3D global area strain (GAS). CTRCD was defined as an absolute decrease in 2D/3D LVEF > 10% to a value < 54% or a relative decrease in 2D GLS > 15%.
RESULTS: 24 patients developed CTRCD. There was a significant worsening of all 3D strain parameters during chemotherapy. 3D strain regional analysis showed impaired contractility in the anterior, inferior, and septal walls. Variations of 3D GRS and 3D GCS were associated with a higher incidence of CTRCD and the variation of 3D GRS was an independent predictor of CTRCD. Variations of 3D GCS and 3D GRS had a good discrimination for predicting CTRCD, with optimal cutoff values of - 34.2% for 3D GCS and - 34.4% for 3D GRS. These variations were observed 45 and 23 days before the diagnosis of CTRCD, respectively.
CONCLUSION: Variations of 3D strain parameters were predictive of and preceded CTRCD, and thus have added value over currently recommended 2D/3D LVEF and 2D GLS. Routine application of this technique should be considered to offer targeted monitoring and timely initiation of cardioprotective treatment.

Entities:  

Keywords:  Anthracyclines; Cardiotoxicity; Speckle-tracking echocardiography; Strain; Three-dimensional

Mesh:

Substances:

Year:  2019        PMID: 31559482     DOI: 10.1007/s00392-019-01556-1

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  5 in total

1.  Use of spectral tracking technique to evaluate the changes in left ventricular function in patients undergoing chemotherapy for colorectal cancer.

Authors:  Zhen Wang; Wenjuan Qin; Zijing Zhai; Lei Huang; Jia Feng; Xueting Guo; Kuican Liu; Caiyun Zhang; Zhong Wang; Guilin Lu; Shanshan Dong
Journal:  Int J Cardiovasc Imaging       Date:  2020-11-27       Impact factor: 2.357

Review 2.  A review of current trends in three-dimensional analysis of left ventricular myocardial strain.

Authors:  Yosuke Nabeshima; Yoshihiro Seo; Masaaki Takeuchi
Journal:  Cardiovasc Ultrasound       Date:  2020-06-26       Impact factor: 2.062

3.  Evaluation of Cardiac Function before and after PAD Regimen in Patients with Multiple Myeloma by Three-Dimensional Speckle Tracking Imaging.

Authors:  Dongliang Chen; Zining Yan; Li Fan; Yifei Rui
Journal:  J Healthc Eng       Date:  2022-01-27       Impact factor: 2.682

4.  A global case meta-analysis of three-dimensional speckle tracking for evaluating the cardiotoxicity of anthracycline chemotherapy in breast cancer.

Authors:  Li Zhang; Rui Zhang; Ping Shuai; Jie Chen; Lixue Yin
Journal:  Front Cardiovasc Med       Date:  2022-09-23

5.  Myocardial Work Brings New Insights into Left Ventricular Remodelling in Cardio-Oncology Patients.

Authors:  Vera Vaz Ferreira; Tania Branco Mano; Isabel Cardoso; Madalena Coutinho Cruz; Luísa Moura Branco; Luís Almeida-Morais; Ana Timóteo; Ana Galrinho; Alexandra Castelo; Pedro Garcia Brás; Diana Simão; Mariana Sardinha; António Gonçalves; Rui Cruz Ferreira
Journal:  Int J Environ Res Public Health       Date:  2022-02-28       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.